Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eiko LifesciencesBOM:540204 +1.38%78 Current Ratio is 3.08 as of Mar. 2026, which is 7% above its 10-year median of 2.89. GuruFocus rates BOM:540204 with a GF Score™ of 78/100 and a GF Value™ of ₹79.11 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,605 Chemicals companies, Eiko Lifesciences ranks better than 73.21% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Eiko Lifesciences's current ratio for the quarter that ended in Mar. 2026 was 3.08.
Eiko Lifesciences has a current ratio of 3.08. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Eiko Lifesciences's Current Ratio or its related term are showing as below:
BOM:540204'
s Current Ratio Range Over the Past 10 Years
Min: 1.02 Med: 2.89 Max: 20.56
Current: 3.08
During the past 13 years, Eiko Lifesciences's highest Current Ratio was 20.56. The lowest was 1.02. And the median was 2.89.
BOM:540204's Current Ratio is ranked better than 73.21% of 1605
companies
in the Chemicals industry
Industry Median: 1.89
vs BOM:540204: 3.08
Eiko Lifesciences (BOM:540204) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Eiko Lifesciences Current Ratio Related Terms
Eiko Lifesciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540204 vs LIN, SHW, ECL: Current Ratio Comparison
For the Specialty Chemicals subindustry, Eiko Lifesciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences Current Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiko Lifesciences (BOM:540204) has a Current Ratio of 3.08 as of Mar. 2026. This is near median its historical median of 2.89. Over the past decade, Eiko Lifesciences' Current Ratio has ranged from 1.02 to 20.56. According to the industry distribution chart, Eiko Lifesciences ranks #430 out of 1605 companies in the Chemicals industry, placing it in the top 26.8%.
Is Eiko Lifesciences' Current Ratio too high?
Eiko Lifesciences' current Current Ratio of 3.08 is near median its 10-year median of 2.89. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 20.56. The Chemicals industry median Current Ratio is 1.89. Eiko Lifesciences' value of 3.08 is 63% above this industry median. Based on the distribution chart, Eiko Lifesciences ranks #430 out of 1605 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' Current Ratio compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #430 out of 1605 companies for Current Ratio. This puts Eiko Lifesciences in the upper half of its industry. The industry median Current Ratio is 1.89. Eiko Lifesciences' value of 3.08 is 63% above this benchmark. Historically, Eiko Lifesciences' own Current Ratio has ranged from 1.02 to 20.56 over the past decade. While the company's 10-year median is 2.89 vs. the industry median of 1.89, Eiko Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Chemicals company?
The median Current Ratio among Chemicals companies is 1.89, based on 1,605 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current Current Ratio of 3.08 is 63% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median Current Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current Current Ratio is 3.08, which is near median its own 10-year median of 2.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹79.11, compared to a current price of ₹49.88 — trading 36.9% below its estimated fair value. The current Current Ratio is 3.08, which is near median its 10-year median of 2.89 and 63% above the Chemicals industry median of 1.89. Eiko Lifesciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current Current Ratio is 3.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹49.88 is trading 36.9% below its estimated GF Value™ of ₹79.11.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
Current Ratio: 3.08 (near median its 10-year median of 2.89)
GF Value™: ₹79.11 vs. price of ₹49.88 (36.9% below fair value)
Industry Position: 63% above the Chemicals median (#430 of 1605)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
78GF Score
Get the complete analysis for BOM:540204
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
